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Abstract:
Background - Left ventricular noncompaction of the myocardium (LVNC) has been 
recognized as a cardiomyopathy with a genetic etiology. Mutations in genes encoding 
sarcomere proteins were shown to be associated with LVNC. We have evaluated the potential 
clinical impact of genetic analysis of sarcomere genes in patients with LVNC.
Methods and Results - In this report, we identified 5 mutations in cardiac myosin-binding 
protein C (MYBPC3) and 2 mutations in Į-tropomyosin (TPM1) in a cohort of unrelated adult 
probands with isolated LVNC. The mutations in MYBPC3 and TPM1 and in 6 other 
previously reported sarcomere genes in this cohort resulted in a total of 18 heterozygous 
mutations in 63 probands (29%). ȕ-myosin heavy chain (MYH7) was the most prevalent 
disease gene and accounts for 13% of cases followed by MYBPC3 (8%). Comparing 
sarcomere mutation-positive and mutation-negative LVNC probands showed no significant 
differences in terms of average age, myocardial function, presence of heart failure or 
tachyarrhythmias at initial presentation or at follow-up. Familial disease was found in 16 
probands of which 8 were sarcomere mutation-positive. Non-penetrance was detected in 2 of 
8 mutation-positive families with LVNC. 
Conclusions - Mutations in sarcomere genes account for a significant proportion of cases of 
isolated LVNC in this cohort (29%). The distribution of disease genes confirms genetic 
heterogeneity and opens new perspectives in genetic testing in patients with LVNC and their 
relatives at high risk of inheriting the cardiomyopathy. The presence or absence of a 
sarcomere gene mutation in LVNC cannot be related to the clinical phenotype. 
 
Key words: cardiomyopathy, genetics, noncompaction, sarcomere 
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Introduction 
Left ventricular noncompaction of the myocardium (LVNC) has been recognized as a 
distinct primary cardiomyopathy with a genetic etiology by the American Heart Association 
whilst it is still considered an unclassified cardiomyopathy according to the European Society 
of Cardiology (ESC).1,2 LVNC is characterized by a unique myocardial morphology, 
hypertrophic segments that consist of a thin compacted epicardial layer and a thick 
noncompacted endocardial layer. The noncompacted layer contains numerous prominent 
trabeculations and deep intertrabecular recesses.3,4 Variable clinical features include both 
asymptomatic and symptomatic patients with the triad of congestive heart failure, 
thrombembolic events, and arrhythmias including sudden cardiac death.3-12 Based upon the 
variation in clinical assessment of family members familial cases were found with a 
frequency between 18% and 64 %.5,6,7,13 As in other cardiomyopathies, index cases represent 
the most severe spectrum of the disease.5,7 Milder and asymptomatic forms and a more 
favorable prognosis of the disease were identified during family screening.10,11,13,14 In 
addition to reports on some very rare disease genes15 mutations in genes encoding sarcomere 
proteins were identified in a significant proportion of LVNC patients.16-18 Heterozygous 
mutations in genes encoding ȕ-myosin heavy chain (MYH7), Į-cardiac actin (ACTC1), and 
cardiac troponin T (TNNT2) account for 17% of cases of isolated LVNC in adult patients.18 In 
a study by Hoedemakers et al., LVNC was associated with genetic variants in 11 of 17 genes; 
6 sarcomere, 2 calcium-handling and other cardiomyopathy genes such as lamin A/C 
(LMNA), ZASP (LDB3), and Taffazin (TAZ).13 Mutations in the genes encoding cardiac 
myosin-binding protein C (MYBPC3), alpha-tropomyosin (TMP1), and cardiac troponin I 
(TNNI3) further supported the concept that sarcomere genes are associated with LVNC.13,19 
Nevertheless, except for one report13 mutation screening efficiency of sarcomere genes is 
uncertain and penetrance and genotype/phenotype correlations in LVNC are unknown.20 In 
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this report we investigated the prevalence, distribution of disease genes, and the spectrum of 
mutations in our systematic study of 8 sarcomere disease genes in 63 adult patients with 
isolated LVNC. We extended our previous mutation analyses to MYBP3 and TMP1. The 
purpose of this study was a combined genetic and phenotypic analysis of this LVNC cohort 
to compare mutation-positive versus mutation-negative probands for possible differences in 
their clinical phenotypes.  
 
Methods
Clinical Evaluation 
Unrelated adult patients were recruited at two tertiary referral centers (University 
Hospital Zürich, Switzerland and the German Heart Institute Berlin, Germany). Informed 
consent was obtained from all participants according to institutional guidelines. Probands and 
available family members were evaluated by history taking, review of medical records, 
physical examination, 12-lead electrocardiography, 24h Holter monitoring, and transthoracic 
echocardiography. Neuromuscular abnormalities were excluded by physical examination. 
The diagnosis of isolated LVNC was made by echocardiography based on the presence of the 
established criteria by Jenni et al.3 Echocardiographic studies were performed/ reviewed by 
two independent observers (RJ and EO).  
 
Mutation Screening 
Mutation screening was carried out with genomic DNA samples from 63 probands as 
described previously.18 Denaturing high performance liquid chromatography (DHPLC) 
analysis of TPM1 and MYBPC3 was performed on the WAVE® Nucleic Acid Fragment 
Analysis System (model 3500HT, Transgenomic, UK) and samples with an abnormal peak 
were sequenced as described previously.8 360 control chromosomes were screened for the 
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absence of a sequence variation to recognize common polymorphisms. The allele frequency 
of the putative mutation in the control population was assumed to be <0.003 given that 360 
control chromosomes were free of the mutation. Mutations were not reported as variants in 
the 1000genomes project (www.1000genomes.org; december 2010 release of 1000G which is 
based on the 2010 08 04 sequence and alignment release). 
 
Statistical Analysis 
Statistical analyses were performed with SPSS for Windows 15.0 (SPSS Inc, Chicago, 
Ill). Mann Whitney test analysis was used for categorical variables. Unpaired Student t test 
analysis was used for continuous variables; a normal distribution of the data was confirmed 
by the Kolmogorov-Smirnov-test. Descriptive data for continuous variables are presented as 
mean ± 1 standard deviation. P values <0.05 were considered to be significant. Probability of 
the event-free rate for the combined end point of death or heart transplantation was calculated 
by the Kaplan-Meier method of life table estimation.  
The authors had full access to and take full responsibility for the integrity of the data. All 
authors have read and agree to the manuscript as written. 
 
Results
A cohort of 63 unrelated Caucasian individuals of western European descent (43 men 
and 20 women; mean age at diagnosis, 40.2 +/- 15.6 years; range 15 to 70 years) underwent 
genetic screening of 8 sarcomere genes. The diagnosis in family members with LVNC was 
ascertained at an age range from 6 weeks to 73 years. Results of a subset of 6 sarcomere 
genes, MYH7, ACTC1, TNNT2, TNNI3, MYL2 and MYL3 in this cohort have previously been 
reported.18 In this report, heterozygous mutations in the same cohort were identified for 2 
other sarcomere genes, in 5 probands in MYBPC3 and in 2 probands in TPM1 (Figure 1). 
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Clinical phenotypes were assessable in 4 families of the 7 probands with MYBPC3 and TPM1
mutations and familial disease was found in 2 of them (Figure 1A). Table 1 shows the 
mutations of probands.21-29 The clinical characteristics of affected family members at initial 
diagnosis are presented in Table 2. A comparison of the clinical characteristics between 
sarcomere mutation-positive and mutation-negative probands was performed (Table 3).  
Mutations in alpha-tropomyosin 
Two novel mutations were found in TPM1. A Glu192 Lys missense mutation in exon 
6 of TPM1 (Figure 1B) was detected in proband KR who suffered from sudden chest pain and 
dyspnea at initial diagnosis. The echocardiogram revealed pronounced LVNC and increased 
right ventricular trabeculations. The mutation affects a glutamic acid with a high degree of 
conservation throughout evolution suggesting its functional importance (Figure 1B). Cardiac 
magnetic resonance imaging (MRI) revealed normal LV mass and extensive diffuse fibrosis 
of the LV (Figure 2A, 2B). Fibrosis was predominantly located on the epicardial side of the 
LV myocardium and extended transmurally into the anterior and inferior LV wall. The 
hypertrophic interventricular septum was spared by fibrosis and appeared without recesses or 
prominent trabeculations. This unusual pattern of fibrosis is not seen in HCM, myocardial 
infarction or myocarditis. Family history revealed that his father had died from heart disease 
at the age of 60 and his uncle from sudden cardiac death at the age of 40. Echocardiography 
of his son, who did not carry the TPM1 mutation showed normal LV morphology and 
function.  
 A novel Lys248Glu missense mutation was identified in exon 8 in the proband of 
family LVNC-117, individual I-1. The patient presented with congestive heart failure at the 
age of 63 years (Figure 2C, 2D). His two affected, asymptomatic children, a 32 year-old 
daughter (II-2) and a 34 year-old son (II-3) were only identified by family screening (Figure 
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1A). The daughter of individual II-2, individual III-1, was suspected to suffer from 
congestive heart failure because of myocarditis several years before description of this family 
history of cardiomyopathy. She was diagnosed with DCM without signs of LVNC; her 
echocardiogram performed at the age of 6 weeks showed biventricular impaired systolic 
function. At the age of 5 years she received a left ventricular assist device and was 
successfully transplanted 3 months later. A diagnostic myocardial tissue sample taken from 
the LV apex revealed pronounced endomyocardial fibroelastosis and minimal interstitial 
fibrosis. Mutation analysis in individual III-1 of all coding exons of the 8 sarcomere genes 
revealed the Lys248Glu mutation in TPM1 but no additional mutation in any of the genes 
tested. 
Mutations in cardiac myosin-binding protein C 
In MYBPC3, 5 mutations were identified, 4 of them were described before in 
individual patients with HCM (Figure 1C). Proband AY presented with atypical chest pain 
and a Gly5Arg sequence variation in exon 2 was detected in this otherwise asymptomatic 
patient. This mutation was also present in his 47 year-old unaffected mother and has been 
reported as a compound heterozygous mutation in a patient with HCM. Two probands, 
individual I-1 of LVNC-102 and LD, carry the same missense mutation (Gly490Arg) in exon 
18. The proband of LVNC-102 was first diagnosed at the age of 70 years because of dyspnea. 
Family screening revealed that his asymptomatic 32-year old son was also affected. Proband 
LD was diagnosed because of unclear syncope. In the two individuals with the Gly490Arg 
mutation, the apex was not affected but only the midventricular inferior and lateral wall 
(Figure 2E). Proband SN presented with decompensated congestive heart failure. In this 
patient the Pro873Leu substitution in exon 27 is a novel mutation. Proband NS had non-
sustained ventricular flutter at electrophysiological investigation and received an ICD (Figure 
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2F). A 2-basepair deletion Pro955ArgfsX95 was detected in her and one of her unaffected 
daughters (14 years-old) that lead to an amino acid frameshift and a premature stop codon 
resulting in a predicted truncated protein. Variants Pro955ArgfsX95 and Gly5Arg represent 
the only 2 cases with familial nonpenetrance in our series. 
 
Genetic and phenotypic analysis of cohort 
63 unrelated probands diagnosed with LVNC underwent genetic screening of 8 
sarcomere genes. Eighteen mutations were identified which accounts for 29 % of all probands 
with isolated LVNC. Fifteen distinct heterozygous mutations were found in 5 sarcomere 
protein genes: MYH7, MYBPC3, TPM1, ACTC1, and TNNT2. No mutations were found in 
TNNI3, MYL2 and MYL3. Mutations occurred most frequently in MYH7 and MYBPC3 with 
13% and 8%, respectively. The frequency of mutations in the 3 other disease genes were: 3% 
in TPM1, 3% in ACTC1 and 2% in TNNT2. Eight of the 15 distinct heterozygous mutations 
were novel mutations: 6 in MYH7, 1 in TPM1 and 1 in MYBPC. The majority of mutations 
were missense mutations (13/18) but 3 splice-site mutations, and 2 deletions, 1 with and 1 
without producing a frameshift were identified. Probands did not carry multiple sarcomere 
mutations. Familial disease was present in 16 probands of which 8 patients were mutation-
positive and 8 were mutation-negative for sarcomere genes. 
A phenotypic comparison between the 18 mutation-positive and 45 mutation negative-
patients was performed (Table 3). Both groups did not differ in sex, age at diagnosis or age at 
follow-up. The duration of follow-up was slightly shorter in the mutation-negative group (p< 
0.046). The following criteria were also not different between the 2 groups at the time of 
diagnosis: (i) number of symptomatic versus asymptomatic patients (dyspnea, syncope, 
shock, palpitations), (ii) tachyarrhythmias (atrial flutter/fibrillation, AV nodal reentrant 
tachycardia, ventricular tachycardia, ventricular flutter/fibrillation), and (iii) heart failure.  
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Echocardiographic criteria also were indistinguishable between the 2 groups: LV 
enddiastolic diameter (LVEDD), LV fractional shortening (LV-FS), LV ejection fraction 
(LV-EF) at diagnosis and at follow-up, respectively. The LV wall was divided into nine 
segments to describe the distribution of affected LVNC segments in the 2 groups: the whole 
apex (one segment); at the base and at the midventricular level, the LV was divided into 4 
segments each (inferior, lateral, anterior and septal). The number of affected segments was 
comparable in both groups (mean was 3 affected segments each). The most prevalent 
locations of LVNC were (mutation negative/mutation-positive): apex (88%/88%), 
midventricular lateral wall (82%/81%), and midventricular inferior wall (76%/88%). Only the 
midventricular septum was more frequently affected in the mutation-positive group 
(8%/31%; p<0.046), but no differences in the distribution of the other 8 segments were found 
between the 2 groups. 
There was no difference between the two groups with regard to the number of 
implantations of an automated cardiac defibrillator. Patients that received a cardiac transplant 
or died were more likely to be found in the mutation-negative group (p<0.048). However, the 
Kaplan-Meyer survival curve for the combined end-point heart transplantation or death did 
not demonstrate any difference between the two groups.  
 
Discussion 
The prevalence, distribution of disease genes, spectrum of mutations and clinical 
features related to mutations in 8 sarcomere genes were investigated in adult patients with 
isolated LVNC. The combined genetic and phenotypic evaluation in this study has 
implications for genetic counseling and testing in LVNC as sarcomere gene mutations are an 
important determinant of LVNC. 
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Prevalence and Spectrum of Sarcomere Gene Mutations in LVNC Patients  
In the total cohort studied, 18 mutations in 5 sarcomere genes were identified in 29% 
of adult patients with isolated LVNC. In the study by Hoedemakers et al.13 mutations in 11 
genes, among them 6 sarcomere genes, in 41% of patients with LVNC were identified. In 
adult patients mutations in MYH7 were the most frequent genetic defects in adult patients: in 
this study in 8 of 63 probands (13 %) and in the study by Hoedemaekers et al.13 in 9 of 57 
probands (16%). Therefore the known prominent role for MYH7 in cardiomyopathies, such as 
in HCM24 and DCM30, is becoming evident in LVNC as well. The study by Hoedemakers et 
al.13 also included children and probands with non-isolated LVNC; patients with Dutch 
founder mutations were reported. Nevertheless, the distribution of mutations in 5 sarcomere 
disease genes was comparable in both cohorts, MYH7 being the most prevalent disease gene 
(20%13 versus 13% in our study) followed by MYBP3 (5%13 versus 8% in our study) and 
mutations in TNNT2, ACTC1 and TPM1 were rare and accounted for LVNC in only 1 or 2 
probands in the respective cohorts. The most prevalent type of mutations in both cohorts was 
missense mutations (16 of 21 distinct mutations13 versus 11 of 15 distinct mutations in our 
study) in MYH7, MYBP3 TNNT2, ACTC1, and TPM1. In addition to 18 probands with single 
mutations Hoedemakers et al.13 described 4 probands with compound or double heterozygote 
mutations and 1 proband had 3 mutations. In contrast, all 18 mutation-positive probands in 
our study carried single mutations.  
Although 8 of the 15 distinct mutations were novel in our cohort it can be anticipated 
that they are not specifically found in LVNC. 7 of the 15 distinct mutations have been 
described before in apical HCM, DCM and HCM. In our previous study18,the Arg243His 
substitution in MYH7 had been found in a patient with apical HCM27, the Glu101Lys 
exchange in ACTC1 in apical HCM and LVNC27,28, and the Arg131Trp substitution in 
TNNT2 in an individual with DCM29. In this study, the exchange Glu192Lys in TPM1 has 
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been reported before in a patient with HCM and atrial septal defect 
(http://www.cardiogenomics.org). The MYBPC3 substitutions Gly5Arg and Gly490Arg were 
found in individuals with HCM.21 The Pro955Arg fsX95 frameshift mutation has been 
reported before in 4 individuals with HCM (3 single mutations, 1 compound heterozygous 
mutation).21,24,25,26 The MYBPC3 Pro873Leu substitution is a novel mutation, a Pro873His 
change has been reported as a homozygous and as a compound heterozygous mutation.22,23 
Therefore, a direct relationship between specific mutations and specific cardiomyopathy 
phenotypes could not be established.  
Penetrance and Variable Phenotypes in LVNC 
The penetrance of a mutation is defined as the percentage of mutation carriers 
expressing a phenotype and most autosomal dominant cardiomyopathies are characterized by 
incomplete penetrance or more age-related penetrance.20 Variants Pro955ArgfsX95 and 
Gly5Arg in MYBPC3 represent the only cases with familial non-penetrance in our series (2/8 
probands). Thus, penetrance in our series of LVNC patients was incomplete but non-
penetrance affected only families with MYBPC3 mutations. Mutations in the most prominent 
disease gene in LVNC, MYH7, were fully penetrant. There is also variable expressivity in 
cardiomyopathies and there can even be large differences between relatives of the same 
family (intra-familial variability) who carry the same mutation. For LVNC this has been 
documented for one family carrying the Glu101Lys exchange in ACTC1 associated with 
apical HCM, LVNC, and septal defects.28 LVNC-117 in this series is an interesting example 
of two cardiomyopathy phenotypes, adult LVNC and neonatal DCM, segregating within one 
family and associated with the same mutation. Intrafamilial differences or a more severe or 
early phenotype are sometimes explained by the presence of a second causal mutation in the 
family.20 For kindred LVNC-117, individual III-1 with neonatal DCM, compound or double 
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heterozygosity or homozygosity in sarcomere genes was excluded and could not account for 
the severe phenotype.  
Familial cardiomyopathy was detected in 25 % of probands. Echocardiography 
revealed LVNC in affected family members, except for family LVNC-117 in which DCM 
was present in one neonate. The number of familial cases in this study is relatively low 
compared to the study by Hoedemaekers at al.13 with a detection of familial cardiomyopathy 
in 64 % of probands due to the almost complete echocardiographic workup of their families. 
In their study 44% of familial disease would have remained undetected by ascertainment of 
family history alone without clinical cardiac family screening. One limitation of our study 
was the incomplete clinical family screening for which position statements have recently 
been published.20,31 Clinical and echocardiographic screening should be considered to detect 
asymptomatic family members with LVNC because of the potentially increased risk for 
arrhythmias, myocardial dysfunction and/or thrombembolic events. In addition, genetic 
evaluation is highly useful for identifying other at-risk relatives without the morphological 
changes as the penetrance of LVNC may be incomplete in some cases. The duration of 
follow-up was shorter in the mutation-negative group and patients that received a cardiac 
transplant or died were more likely to be found in the mutation-negative group. Therefore the 
mutation-positive group seems to have a slightly more benign clinical phenotype. Long-term 
studies are needed to detect possible relationships between the type of mutation, genetic 
modifiers and clinical phenotype. 
LVNC: a defect of cardiomyocyte dysfunction during myocardial development? 
How mutations in sacromere genes could have detrimental effects on cardiac 
morphogenesis is unclear. LVNC is still considered an unclassified cardiomyopathy by the 
ESC2 and other investigators32,33 who suggest that it is not clear whether it is a separate 
 at Universitaet Zuerich on December 28, 2011circgenetics.ahajournals.orgDownloaded from 
13 
 
cardiomyopathy or merely a morphological trait shared by many phenotypically distinct 
cardiomyopathies. Biagini reported a series of LVNC patients in which patients fulfilled 
echocardiographic critera for DCM, HCM and restrictive cardiomyopathy.34 The causal role 
of noncompaction in the pathogenesis of cardiomyopathy was recently questioned by 
transgenic mice carrying a human troponin T mutation leading to LVNC in patients.35 
Not much is known about the molecular regulation of ventricular trabeculation. Early 
myocardial development is characterized by a subdivision of the myocardial wall into an 
outer highly mitotic compact zone and an inner trabecular zone with much less proliferative 
activity. A correct balance between proliferation and differentiation of cardiomyocytes seems 
to be critical in ventricular chamber formation.36 In zebrafish Aumann and collegues37 
demonstrated that chamber morphology develops via changes in cell morphology. Their 
model suggests that even subtle changes of circulation or contractility caused by mutated 
sarcomere genes could lead to abnormalities in cell morphology and consequences for 
chamber morphology. How this model could account for the localized remodeling of the 
ventricular apex, which is primarily affected in LVNC, remains to be determined.  
In this study several mutations in MYBPC3 were found in LVNC. In HCM, most 
MYBPC3 mutations are predicted to produce C-terminally truncated proteins, lacking titin 
and/or major myosin binding sites. Recent work strongly argues for haploinsufficiency as the 
disease mechanism for both, truncation and missense MYBPC3 mutations. 38,39 The 
sarcomeric phenotype in HCM with MYBPC3 mutations includes a primary contractile 
sarcomeric defect causing deranged secondary alterations in protein phosphorylation.25 It 
remains to be determined if contractile dysfunction is the pivotal link between mutant 
sarcomeric protein and the pathological morphology observed in LVNC. 
Conclusions 
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In this cohort of adult patients with isolated LVNC mutations in sarcomere genes have a 
prominent role with a prevalence of 29%. Of the 8 genes tested, MYH7 and MYBPC3 are the 
most frequently mutated sarcomere genes in LVNC, 13% and 8 % respectively. Sarcomere 
mutation-positive probands cannot be distinguished from mutation-negative probands on the 
basis of their clinical phenotypes. However, genetic testing of sarcomere genes is a valuable 
diagnostic tool for the probands and their relatives at high risk of inheriting the 
cardiomyopathy. 
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Table 1. Mutations of 63 LVNC Probands 
Mutation Probands ID 
Transcript Protein Exon Reference 
New mutations, this study  
TPM1     
Sporadic KR c.765G>A p.Glu192Lys 6 This study; 
http://www.cardiogenomics.org 
LVNC-117 I-1 c.933A>G p.Lys248Glu 8 This study, novel 
MYBPC3        
Sporadic AY c.68G>A p.Gly5Arg 2 This study; [21] compound 
heterozygous with 
Arg502Trp 
LVNC-102 I-1 c.1523G>A p.Gly490Arg 18 This study; [21] 
Sporadic LD c.1523G>A p.Gly490Arg 18 This study; [21] 
Sporadic  SN c.2673C>T p.Pro873Leu 27 This study, novel; [22,23] 
Pro873His  
Sporadic  NS c.2919-2920delCT p.Pro955ArgfsX95 28 This study; [21]; [24,25,26] 
compound heterozygous with 
Glu258Lys 
Mutations previously published by Klaassen et al. [18] 
MYH7      
LVNC-101 II-4 c.818+1G>A   [18] 
LVNC-107 II-3 c.814G>A p.Arg243His 8 [18,27] 
LVNC-108 II-2 c.818+1G>A   [18] 
LVNC-109 II-1 c.818+3G>C   [18] 
Sporadic  AJ c.801_803delGAC p.Asp239del 8 [18] 
Sporadic  SD c.840T>C p.Phe252Leu 9 [18] 
Sporadic  IP c.4161C>T p.Arg1359Cys 30 [18] 
Sporadic  MT c.5382G>A p.Ala1766Thr 37 [18] 
ACTC1         
LVNC-110 LJ c.478G>A p.Glu101Lys 2 [18,27,28] 
LVNC-111 SA c.478G>A p.Glu101Lys 2 [18,27,28] 
TNNT2         
Sporadic  CR c.450C>T p.Arg131Trp 10 [18,29] 
Sporadic, only the proband of a family was affected with LVNC; LVNC-101, -102, -107, -108, -109, -
110, -111, -117, familial disease, apart from the proband at least one more affected individual with 
LVNC in a family 
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Table 2. Clinical Characteristics of Affected Family Members at Initial Diagnosis  
    Echocardiography  
Probands ID Age(y) /Sex NYHA 
Site of 
LVNC* 
LVEDD
Z-score 
EF/FS 
(%) 
Cardiovascular 
complications 
TPM1               
LVNC-117 I-1 63/M 4 2 3.4 19/18 CHF 
 II-2 32/F 1 1 1 37/20 None 
 II-3 34/M 1 1 1 53/32 None 
 III-1 0/F 3 0 4.0 22/16 CHF, AF, HTX at 5 y 
Sporadic  KR 55/M 2 2 1.2 42/NA None 
MYBPC3               
Sporadic AY 20/M 1 2 0.7 55/25 None 
LVNC-102   I-1 70/M 2 3 0.3 72/33 None 
 II-1 32/M 1 3 0.4 60/38 None 
Sporadic LD 24/F 1 3 0.5 57/29 Syncopes 
Sporadic SN 37/M 4 2 3.0 28/18 CHF, PHT 
Sporadic  NS 28/F 2 2 1.7 46/25 NSVT at EPI, ICD 
* Noncompacted segments: no=0; apex=1; apex, midventricular wall=2; midventricular wall=3; LVEDD, left 
ventricular enddiastolic diameter; Z score, normal reference  range -2 <  +2; EF/FS, left ventricular ejection 
fraction/fractional shortening; AF, atrial fibrillation; CHF, congestive heart failure; PHT, pulmonary 
hypertension;  ICD, intracardiac defibrillator; NSVT, nonsustained ventricular tachycardia; HTX, heart 
transplantation; EPI, electrophysiologic investigation; Sporadic, only the proband of a family was affected with 
LVNC; LVNC-102, -117, familial disease, apart from the proband at least one more affected individual with 
LVNC in a family 
Table 3.  Comparison of Probands with and without Sarcomere Gene Mutations  
 Mutation-positive 
n=18 
Mutation-negative 
n=45 
P
Sex M/F, n 13/5 30/15 NS 
Age (D), y 39.2±16.9 43.3±15.0 NS 
Age (FU), y 45.5±16.6 46.8±15.7 NS 
Duration of FU, y 6.7±5.5 3.8±4.2 0.046 
At diagnosis (D)    
Cardiac symptoms, n (%) 14 (78) 40 (89) NS 
Heart failure, n (%) 10 (56) 28 (62) NS 
Tachyarrhythmias, n (%) 2 (11) 7 (16) NS 
Echocardiography    
LVED (D/FU, y) 60.0±9.2/ 59.7±9.0 60.0±12.3/ 58.4±10.2 NS 
LV-FS (D/FU, y) 20.0±9.3/ 22.2±10.3 22.9±8.9/ 23.4±11.1 NS 
LV-EF (D/FU, y)  36.1±17.1/ 39.6±14.4 38.7±16.1/ 42.3±15.1 NS 
At follow-up (FU)    
ICD, n (%) 3 (17) 7 (16) NS 
Alive /HTX or death, n (%)* 16 (89)/ 2(11) 36(80)/ 9(20) 0.048 
At diagnosis (D) /at follow-up (FU) Cardiac symptoms (dyspnea, syncope, shock, palpitations); Heart failure 
(NYHA II-IV); Tachyarrhythmias (atrial flutter/fibrillation, AV nodal reentrant tachycardia, ventricular 
tachycardia, ventricular flutter/fibrillation); ICD, intracardiac defibrillator; LVED, left ventricular enddiastolic 
diameter; EF/FS, left ventricular ejection fraction/fractional shortening; HTX, heart transplantation; Values are 
given as mean ± standard deviation; * from18 mutation-positive probands 16 were alive and 2 were deceased or 
had received a cardiac transplant, from 45 mutation-negative probands 36 were alive and 9 were deceased or 
had received a cardiac transplant. 
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Figure Legends: 
Figure 1. A. Pedigrees of kindreds LVNC-102 (mutation in MYBPC3, Gly490Arg) and 
LVNC-117 (mutation in TPM1, Lys248Glu) with autosomal dominant LVNC. Filled 
symbols indicate individuals with LVNC; open symbols, unaffected status; shaded symbols, 
unknown clinical status. Plus signs (+) indicate the presence of a mutation, and minus signs (-
) the absence of a mutation. B. Alignment of the regions flanking the novel mutations in 
TPM1 showing evolutionary conservation of the mutated residues across species. The 
residues with the novel amino acid changes in LVNC are boxed. Dots identify amino acids 
identical to the one in the human sequence. C. Schematic domain structure of cardiac myosin 
binding protein -C (cMYBP-C) protein with the location of mutations in the encoding gene 
MYBPC3. cMYBP-C consists of 8 immunoglobulin (Ig)-like and 3 fibronectin (Fn3) domains 
with binding sites for myosin and titin. The N-terminal C0 is specific for cMYBP-C. The 
cardiac-specific phosphorylation sites are located between C1 and C2. The MYBPC3
missense mutations were found in different regions of the molecule. The CT deletion in exon 
28 (c.2919-2920delCT) creates a frameshift resulting in a premature termination codon in 
exon 30. 
 
Figure 2. A, B Magnetic resonance images, short axis orientation at midventricular level, of 
individual KR with a Glu192 Lys mutation in TPM1. A, SSFP image: thin epicardial and 
trabeculated endocardial layer of the myocardium. B, Late gadolinium enhancement image: 
scar tissue (bright region) in the heavily trabeculated areas (anterior, inferior) while the 
septum and parts of the lateral wall are not affected (black). C-F Echocardiographic images 
of affected individuals with LVNC. C, Enddiastolic parasternal short axis and D, enddiastolic 
apical 4-chamber view of individual I-1 of kindred LVNC-117. E, Enddiastolic parasternal 
short axis view of individual LD with midventricular LVNC. F, Enddiastolic 4-chamber view 
of proband NS with apical and midventricular LVNC.
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